Skip to main content
SpringerLink
Log in
Book cover

Resistance of Cancer Cells to CTL-Mediated Immunotherapy

  • Book
  • © 2015

Overview

Editors:
  1. Benjamin Bonavida

    1. Department of Microbiology, Immunology a, University of California at Los Angeles,, Los Angeles, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Salem Chouaib

    1. Institut Gustave Roussy, Villejuif, France

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Explores the inhibition of CTL-cytotoxic function by tumor-derived T-regulatory cells, along with the inhibition of cytotoxic function by tumor induction of hypoxia
  • Discusses the overexpression of transcription factors that regulate resistance
  • Appeals to cancer researchers, biologists and immunologists

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 7)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (15 chapters)

  1. Front Matter

    Pages i-xix
    Download chapter PDF

  2. Factors Regulating Resistance to CTL Cytotoxicity

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses

      • Veronica Catalano, Cecilia Eleuteri, Gaia Campoccia, Gianluca Giacobini, Mariangela Zane, Giorgio Stassi et al.
      Pages 3-29

    3. Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack

      • Wieger J. Norde, Willemijn Hobo, Harry Dolstra
      Pages 31-58

    4. Role of the Non-classical HLA Class I Antigens for Immune Escape

      • Barbara Seliger, Simon Jasinski-Bergner
      Pages 59-72

    5. Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response

      • Marie Boutet, Stephanie Cognac, Fathia Mami-Chouaib
      Pages 73-89

    6. Cytotoxic T Lymphocytes and Their Granzymes: An Overview

      • Janis Noonan, Brona M. Murphy
      Pages 91-112

  3. Influence of the Tumor Microenvironment on the Resistance to CTL Cytotoxicity

    1. Front Matter

      Pages 113-113
      Download chapter PDF

    2. Hypoxia: A Formidable Saboteur of the Anti-tumor Response

      • Meriem Hasmim, Yosra Messai, Stéphane Terry, Bassam Janji, Muhammad Zaeem Noman, Salem Chouaib
      Pages 115-142

    3. Mechanisms and Modulation of Tumor Microenvironment-Induced Immune Resistance

      • Tuna Mutis, Niels W. C. J. van de Donk, Richard W. J. Groen
      Pages 143-158

    4. Evasion of Cytotoxic Lymphocyte and Pulmonary Macrophage-Mediated Immune Responses in Lung Cancer

      • Sandra Hodge, Greg Hodge
      Pages 159-174

  4. Resistance to Death Ligands-Mediated Apoptosis and Sensitization

    1. Front Matter

      Pages 175-175
      Download chapter PDF

    2. Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop

      • Benjamin Bonavida
      Pages 177-208

    3. Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies

      • Julianne D. Twomey, William Hallett, Baolin Zhang
      Pages 209-233

    4. Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex

      • Yabing Chen, Kaiyu Yuan, Jay McDonald
      Pages 235-265

    5. Epithelial Mesenchymal Transition Influence on CTL Activity

      • Wilfried Engl, Virgile Viasnoff, Jean Paul Thiery
      Pages 267-284

  5. Future Directions and Challenges

    1. Front Matter

      Pages 285-285
      Download chapter PDF

    2. Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors

      • Yutaka Kawakami, Li Qian, Naoshi Kawamura, Junichiro Miyazaki, Kinya Tsubota, Tomonari Kinoshita et al.
      Pages 287-301

    3. Quality of CTL Therapies: A Changing Landscape

      • Krishnamurthy Thyagarajan, Shilpak Chatterjee, Pravin Kesarwani, Michael I. Nishimura, Shikhar Mehrotra
      Pages 303-349

  6. ERRATUM TO: Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response

    • Marie Boutet, Stephanie Cognac, Fathia Mami-Chouaib
    Pages E1-E1
Back to top

Keywords

About this book

This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.

Editors and Affiliations

  • Department of Microbiology, Immunology a, University of California at Los Angeles,, Los Angeles, USA

    Benjamin Bonavida

  • Institut Gustave Roussy, Villejuif, France

    Salem Chouaib

About the editors

Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.

Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.

Bibliographic Information

  • Book Title: Resistance of Cancer Cells to CTL-Mediated Immunotherapy

  • Editors: Benjamin Bonavida, Salem Chouaib

  • Series Title: Resistance to Targeted Anti-Cancer Therapeutics

  • DOI: https://doi.org/10.1007/978-3-319-17807-3

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing Switzerland 2015

  • Hardcover ISBN: 978-3-319-17806-6Published: 30 June 2015

  • Softcover ISBN: 978-3-319-38067-4Published: 17 October 2016

  • eBook ISBN: 978-3-319-17807-3Published: 20 June 2015

  • Series ISSN: 2196-5501

  • Series E-ISSN: 2196-551X

  • Edition Number: 1

  • Number of Pages: XIX, 353

  • Number of Illustrations: 11 b/w illustrations, 27 illustrations in colour

  • Topics: Cancer Research, Drug Resistance, Molecular Medicine

Publish with us

Policies and ethics

Back to top

Search

Navigation